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Editorial
Future direction ofmedical genetics
Thegeneticrevolutionbeganin 1953whenCrick
and Watson proposed the double-helix structure
ofDNA. On 26th June 2000, the firstdraft ofthe
3.2 billion bases of DNA (the human genome)
was made public. The completion of the
sequencing of human DNA, undoubtedly the
greatest biological achievement will have major
implications for the future direction of medical
genetics andmedicine. Thepractical value ofthe
completed DNA sequence will be to provide
more rapid approaches in the search for disease-
causing genes which will lead to the unravelling
themolecularbasisofdisease.Itwillalsoprovide
techniques for accurate and improved diagnosis
andforthepresymptomatic screening of 'atrisk'
individuals within families and populations. An
understanding ofthe genetic factors involved in
multifactorialconditions, suchasischaemicheart
disease and diabetes, will result in the
developmentofpersonalizedprevention,tailored
drug treatment and eventually 'cure.'
The clinical geneticist's primary function will
continue to be the provision of diagnosis and
counselling of families with genetic and partly
genetic disorders. They willhavethefacilities to
make accurate diagnoses and to screen family
relatives moreefficiently forthe disease causing
gene mutations. It will be possible to make
accurate assessment ofrisk and to provide more
detailed information to enable patients and their
relatives to make informed decisions. As many
clinicaldisciplines embracemolecularmedicine,
the clinical geneticist willbe amemberin multi-
discipline teams managing patients with single
gene defects and complex disorders Clinicians
will have direct access to analysis of gene
expression using DNA micro-array technology.
This will enable the simultaneous analysis of a
thousands of unique DNA fragments, each
fragmentabletodetectmRNAexpressedfromits
corresponding gene. Micro-arrays have huge
potential for many different fields in medicine,
particularlyingeneexpressionpatternrecognition
which characterizes disease states.' Gene
expression profiling will not only be useful for
haematological diseases and cancers, but also in
unravelling the molecular aetiology of learning
disability, skeletal dysplasias and 'dysmorphic'
syndromes.Chromosomalanalysis(cytogenetics)
remains the main diagnostic test for learning
disability,geneticsyndromesandforreproductive
loss and infertility. Currently, chromosomal
abnormalities are diagnosed by conventional G-
orR-banding methods butnew techniques based
on DNA hybridisation (FISH), spectral
karyotyping (SKY) and spectral colour banding
(SCAN) will enhance the ability of clinical
cytogeneticlaboratoriestodetectsubtlegenomic
changes.2 The development of whole genome
matrix-comparative genomic hybridisation is
likelytoachievearesolutionequivalenttothatof
standard ofG-banding. A whole genome micro-
arraywillbeidealforscreeningformicrodeletions
and microduplications and will greatly assist in
theidentificationofcryptictelomericaberrations
which have a role in unexplained learning
disabilityanddysmorphic syndromes. Itwillalso
be a valuable asset in the study ofchromosomal
aberrationsincancerandwillhaveamajorimpact
on the understanding of disease, disease
progression and outcome and also on responses
to drug and radiotherapy treatments.
Clinicalgeneticistsandobstetriciansareinvolved
in assessing the health of the human fetus. A
major challenge is to develop methods which do
not compromise the fetus. Currently, prenatal
diagnosis ofchromosomal abnormalities such as
Down syndrome and gene disorders such as
Duchenne muscular dystrophy can only be
accurately achievedbychorionvillusbiopsyand
amniocentesis which are associated with a 1-5%
fetal loss. In the future, clinicians will be able to
screen the fetus for chromosomal abnormalities
andgenedisordersonmaternalbloodat 10weeks
gestation. The recentdiscovery ofacellularfetal
DNA in plasma from pregnant women offers an
alternative to invasive procedures.3 Many
pregnant women who are 'at risk' of having an
infantwith asingle gene disorderoracongenital
abnormality are reluctant to undergo prenatal
diagnosis because abortion is unacceptable.
Another approach for such women will be
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preimplantation genetic diagnosis(PGD) which
will avoidthebirth ofaffectedchildren.4 Several
embryos are produced by IVF and cultured for 3
days to reach a 6-10 cell stage. One or two cells





trisomies and afew gene disorders such as cystic
fibrosis and Duchenne muscular dystrophy. The
goal in medicine is to 'cure' disease.
Understanding the molecular basis of genetic
disorders offers the possibility of correction of
thegenedefect. Genetherapyisonly 10yearsold
but despite set-backs and obstacles, evidence
now is emerging of beneficial outcomes. Trials
of gene therapy for severe combined immune
deficiency(SCID) and haemophilia have
demonstrated that it is possible to restore and
maintain normal gene function. Currently gene
therapy involves the delivery of the wild type
(normal) gene into the affected cells but within
thenextdecademoreefficientapproacheswillbe
available such as gene repair, engineered exon
skipping and 'in utero' gene therapy.5
Theadvancesinhumangeneticsraisemanylegal,
ethicalandsocialissues. Clinicalgeneticists will
become increasingly involved in public debate
about the application of genetic knowledge not
only to families but also to society. Despite the
potential for misuse ofgenetic knowledge, there
are enormous benefits of the 'new genetics' to
tomorrow's clinical geneticists and physicians.
When questioned about the implications of the
sequencing of the human genome, J D Watson
replied, "Use it . .. to understand more about
disease, prevent genetic diseases coming into
existence and possibly finding a way to cure
them." Clinicalgenetics has anpromisingfuture.
N. C. Nevin
C) The Ulster Medical Society, 2001.
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